No connection

Search Results

ABBV vs INSP

ABBV
AbbVie Inc.
NEUTRAL
Price
$219.26
Market Cap
$387.52B
Sector
Healthcare
AI Confidence
68%
INSP
Inspire Medical Systems, Inc.
BULLISH
Price
$55.11
Market Cap
$1.59B
Sector
Healthcare
AI Confidence
85%

Valuation

P/E Ratio
ABBV
163.63
INSP
11.27
Forward P/E
ABBV
15.42
INSP
21.32
P/B Ratio
ABBV
-146.66
INSP
2.02
P/S Ratio
ABBV
6.5
INSP
1.74
EV/EBITDA
ABBV
15.27
INSP
20.02

Profitability

Gross Margin
ABBV
71.46%
INSP
85.39%
Operating Margin
ABBV
35.5%
INSP
17.14%
Profit Margin
ABBV
4.0%
INSP
15.95%
ROE
ABBV
137.96%
INSP
19.77%
ROA
ABBV
9.59%
INSP
3.71%

Growth

Revenue Growth
ABBV
9.1%
INSP
12.2%
Earnings Growth
ABBV
-88.7%
INSP
308.4%

Financial Health

Debt/Equity
ABBV
--
INSP
0.04
Current Ratio
ABBV
0.72
INSP
6.08
Quick Ratio
ABBV
0.47
INSP
4.46

Dividends

Dividend Yield
ABBV
3.05%
INSP
--
Payout Ratio
ABBV
490.15%
INSP
0.0%

AI Verdict

ABBV NEUTRAL

The Advanced Deterministic Scorecard reveals a mixed health profile with a Piotroski F-Score of 4/9 indicating stable but not strong fundamentals, while the absence of an Altman Z-Score prevents a clear distress risk assessment. Despite robust operating margins and consistent revenue growth, the company faces significant headwinds from negative earnings growth, an extremely high P/E ratio, and a dangerously elevated payout ratio. Strong historical price performance and analyst buy sentiment are counterbalanced by bearish insider activity and deteriorating profitability trends. The stock appears to trade at a substantial premium to its intrinsic value, suggesting limited margin of safety.

Strengths
High operating margin (35.50%) indicating strong pricing power and cost control
Consistent revenue growth (9.10% YoY) outpacing sector average
Strong track record of earnings surprises (22 out of 25 quarters beat estimates)
Risks
Extremely high P/E ratio (163.63) vs forward P/E (15.42), suggesting potential overvaluation on trailing basis
Earnings growth collapsing (YoY: -88.70%, Q/Q: -88.10%) indicating severe profitability deterioration
Unsustainable dividend payout ratio (490.15%) threatening dividend security
INSP BULLISH

INSP exhibits strong fundamental health with a Piotroski F-Score of 7/9 and an exceptionally clean balance sheet (Debt/Equity 0.04). While the stock has suffered a severe multi-year price collapse, it is currently trading almost exactly at its Graham Number ($54.84), suggesting it has reached a defensive valuation floor. The massive disconnect between the current price ($55.11) and the growth-based intrinsic value ($144.25), coupled with explosive earnings growth (308.4% YoY), presents a compelling value-growth opportunity. Despite bearish technicals and insider selling, the underlying profitability and liquidity metrics are superior to sector averages.

Strengths
Strong financial health indicated by Piotroski F-Score of 7/9
Exceptional gross margins (85.39%) and healthy ROE (19.77%)
Negligible debt levels (Debt/Equity 0.04) and high liquidity (Current Ratio 6.08)
Risks
Severe long-term price deterioration (5Y Change: -77.1%)
Bearish insider sentiment with recent selling activity
Strongly bearish technical trend (0/100 score)

Compare Another Pair

ABBV vs INSP: Head-to-Head Comparison

This page compares AbbVie Inc. (ABBV) and Inspire Medical Systems, Inc. (INSP) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.

Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.

Home
Terminal
AI Chat
Markets
Profile